| Dr Antony Eugin Martin, MD | |
|
5121 S Cottonwood St, Murray, UT 84107-5701 | |
| (801) 507-1650 | |
| Not Available |
| Full Name | Dr Antony Eugin Martin |
|---|---|
| Gender | Male |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 29 Years |
| Location | 5121 S Cottonwood St, Murray, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174805162 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | 9376066-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Intermountain Medical Center | Murray, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
Researchers at The Hospital for Sick Children (Sick Kids) have found that a new topical anaesthetic (liposomal lidocaine 4% cream, brand name Maxilene) effectively reduced pain for children having IVs inserted (cannulation) in the emergency department and improved procedural success rates.
Perrigo today announced that its licensor and supplier Synthon has received final approval from the U.S. Food and Drug Administration (FDA) for Levocetirizine tablets, a generic version of Xyzal® tablets from UCB/Sepracor, which is marketed in the U.S. by Sanofi-Aventis. Perrigo has the exclusive rights from Synthon to sell and distribute the product in the U.S.
Roche Molecular Diagnostics announced today that the Food and Drug Administration (FDA) approved its new dual-PCR target HIV-1 viral load test to quantify the amount of virus in a patient's blood. The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 is the first quantitative viral load test to amplify and detect two separate regions of a target genome and offers a fully automated and reliable solution for physicians to make informed treatment decisions for HIV-1 patients undergoing antiretroviral therapy.
A team of scientists from Sweden and India has recently conducted a study to evaluate type I interferon (IFN-I) responses in cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The findings reveal that SARS-CoV-2 infection is associated with a delayed and dysregulated IFN-I response and that pretreatment with IFN-I can reduce the risk of SARS-CoV-2 infection.
A cellular molecule that not only can sense two common respiratory viruses but also can direct cells to mount a defense has been identified by microbiologists at The University of Texas Health Science Center at San Antonio.
› Verified 9 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629260880 PECOS PAC ID: 1850209420 Enrollment ID: O20031105000079 |
News Archive
Researchers at The Hospital for Sick Children (Sick Kids) have found that a new topical anaesthetic (liposomal lidocaine 4% cream, brand name Maxilene) effectively reduced pain for children having IVs inserted (cannulation) in the emergency department and improved procedural success rates.
Perrigo today announced that its licensor and supplier Synthon has received final approval from the U.S. Food and Drug Administration (FDA) for Levocetirizine tablets, a generic version of Xyzal® tablets from UCB/Sepracor, which is marketed in the U.S. by Sanofi-Aventis. Perrigo has the exclusive rights from Synthon to sell and distribute the product in the U.S.
Roche Molecular Diagnostics announced today that the Food and Drug Administration (FDA) approved its new dual-PCR target HIV-1 viral load test to quantify the amount of virus in a patient's blood. The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 is the first quantitative viral load test to amplify and detect two separate regions of a target genome and offers a fully automated and reliable solution for physicians to make informed treatment decisions for HIV-1 patients undergoing antiretroviral therapy.
A team of scientists from Sweden and India has recently conducted a study to evaluate type I interferon (IFN-I) responses in cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The findings reveal that SARS-CoV-2 infection is associated with a delayed and dysregulated IFN-I response and that pretreatment with IFN-I can reduce the risk of SARS-CoV-2 infection.
A cellular molecule that not only can sense two common respiratory viruses but also can direct cells to mount a defense has been identified by microbiologists at The University of Texas Health Science Center at San Antonio.
› Verified 9 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
Researchers at The Hospital for Sick Children (Sick Kids) have found that a new topical anaesthetic (liposomal lidocaine 4% cream, brand name Maxilene) effectively reduced pain for children having IVs inserted (cannulation) in the emergency department and improved procedural success rates.
Perrigo today announced that its licensor and supplier Synthon has received final approval from the U.S. Food and Drug Administration (FDA) for Levocetirizine tablets, a generic version of Xyzal® tablets from UCB/Sepracor, which is marketed in the U.S. by Sanofi-Aventis. Perrigo has the exclusive rights from Synthon to sell and distribute the product in the U.S.
Roche Molecular Diagnostics announced today that the Food and Drug Administration (FDA) approved its new dual-PCR target HIV-1 viral load test to quantify the amount of virus in a patient's blood. The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 is the first quantitative viral load test to amplify and detect two separate regions of a target genome and offers a fully automated and reliable solution for physicians to make informed treatment decisions for HIV-1 patients undergoing antiretroviral therapy.
A team of scientists from Sweden and India has recently conducted a study to evaluate type I interferon (IFN-I) responses in cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The findings reveal that SARS-CoV-2 infection is associated with a delayed and dysregulated IFN-I response and that pretreatment with IFN-I can reduce the risk of SARS-CoV-2 infection.
A cellular molecule that not only can sense two common respiratory viruses but also can direct cells to mount a defense has been identified by microbiologists at The University of Texas Health Science Center at San Antonio.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Antony Eugin Martin, MD Po Box 27128, Salt Lake City, UT 84127-0128 Ph: (801) 507-1650 | Dr Antony Eugin Martin, MD 5121 S Cottonwood St, Murray, UT 84107-5701 Ph: (801) 507-1650 |
News Archive
Researchers at The Hospital for Sick Children (Sick Kids) have found that a new topical anaesthetic (liposomal lidocaine 4% cream, brand name Maxilene) effectively reduced pain for children having IVs inserted (cannulation) in the emergency department and improved procedural success rates.
Perrigo today announced that its licensor and supplier Synthon has received final approval from the U.S. Food and Drug Administration (FDA) for Levocetirizine tablets, a generic version of Xyzal® tablets from UCB/Sepracor, which is marketed in the U.S. by Sanofi-Aventis. Perrigo has the exclusive rights from Synthon to sell and distribute the product in the U.S.
Roche Molecular Diagnostics announced today that the Food and Drug Administration (FDA) approved its new dual-PCR target HIV-1 viral load test to quantify the amount of virus in a patient's blood. The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 is the first quantitative viral load test to amplify and detect two separate regions of a target genome and offers a fully automated and reliable solution for physicians to make informed treatment decisions for HIV-1 patients undergoing antiretroviral therapy.
A team of scientists from Sweden and India has recently conducted a study to evaluate type I interferon (IFN-I) responses in cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The findings reveal that SARS-CoV-2 infection is associated with a delayed and dysregulated IFN-I response and that pretreatment with IFN-I can reduce the risk of SARS-CoV-2 infection.
A cellular molecule that not only can sense two common respiratory viruses but also can direct cells to mount a defense has been identified by microbiologists at The University of Texas Health Science Center at San Antonio.
› Verified 9 days ago
Dr. John B Hijjawi, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 5169 S Cottonwood St Ste 420, Murray, UT 84107 Phone: 801-507-1650 | |
Robert Edward Hugh Ferguson Jr., M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 5169 Cottonwood St, Suite 410, Murray, UT 84107 Phone: 801-507-1650 Fax: 801-233-4410 | |
Megan Lehane Delano, PA-C Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 5169 Cottonwood St Ste 420, Murray, UT 84107 Phone: 801-507-1650 | |
Brenton Robinson, M.D. Plastic Surgery Medicare: Medicare Enrolled Practice Location: 5292 S College Dr Ste 302, Murray, UT 84123 Phone: 801-293-8100 | |
Dr. Larry Kent Patton, MD Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 5169 Cottonwood St, #410, Murray, UT 84107 Phone: 801-507-1650 | |
Mr. John Michael Self, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 5292 So College Dr, 202, Murray, UT 84123 Phone: 801-266-3671 Fax: 801-266-8194 |